| Name | Prednisolone hemisuccinate |
| Description | Prednisolone hemisuccinate is a soluble glucocorticoid and cortisol, a prodrug of the glucocorticoid (GR) agonist Prednisone, which exerts anti-inflammatory, immunosuppressive, and antiallergic effects by binding to GR receptor, and is commonly used in systemic lupus erythematosus, acute dermatologic conditions, and arthritis. |
| In vitro | Methods: Peripheral blood mononuclear cells containing NK cells were isolated and cocultured with target K562 cells at three different effector-to-target (E:T) ratios of 50:1, 25:1, and 12.5:1. Prednisolone hemisuccinate or IVIG were then added to the tubes at an E:T ratio of 50:1 to assess the inhibitory effect. Percent killing was recorded and statistically analyzed using the Student t test.
Results: In experiments with an E:T ratio of 50:1 and either Prednisolone hemisuccinate or IVIG in the coculture, the mean target cell killing rate was 26.4%. In cultures using the same E:T ratio, this killing rate was significantly reduced in the presence of IVIG (9.9%) or Prednisolone hemisuccinate (13.6%) (P < 0.001 for both analyses). Prednisolone hemisuccinate was able to inhibit the cytolytic activity of NK cells. [1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (8.69 mM), Sonication is recommended.
DMSO : 150 mg/mL (325.72 mM), Sonication is recommended.
|
| Keywords | Prednisolone hemisuccinate | Prednisolone |
| Inhibitors Related | Nimodipine | Betamethasone | Mifepristone | Prednisone | Prednisolone acetate | Cortisone | Dexamethasone acetate | Dexamethasone | Betamethasone dipropionate | Dexamethasone Phosphate disodium | Prednisone acetate | Desonide |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Bioactive Compound Library | Bioactive Compounds Library Max | Bioactive Lipid Compound Library |
United States
